We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Breakthrough Diagnostic Approach to Significantly Improve TB Detection

By LabMedica International staff writers
Posted on 24 Apr 2025
Print article
Image: The breakthrough approach for diagnosing TB could significantly improve detection (Photo courtesy of 123RF)
Image: The breakthrough approach for diagnosing TB could significantly improve detection (Photo courtesy of 123RF)

Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying TB, preventing its spread, and ultimately working towards its eradication. TB can remain dormant in the body for years without causing symptoms, but it may become active later, particularly in individuals at high risk. Therefore, accurate testing for both active and dormant TB infections is critical for effective screening programs. Current TB testing methods include chest X-rays, sputum cultures, molecular tests, symptom screenings, and skin or blood tests to detect dormant TB infections (TBI). All these methods aim to accurately identify TB with minimal false positives to avoid unnecessary treatments. Now, a new strategy for TB screening addresses the limitations of existing methods, which often fail to detect the disease accurately.

Simultaneously screening for both active and dormant TB infections could significantly reduce infection rates, save lives, and alter the ongoing spread of the disease, according to a new study by researchers at Queen Mary University of London (QMUL, London, UK). The researchers hope that this novel approach, detailed in the European Respiratory Journal, will influence global health organizations and policymakers in defining the most effective screening strategies for TB. In the study, the research team evaluated the effectiveness of combining commonly used TB tests. Their study reviewed data from 437 original studies and published systematic reviews involving 13 different TB tests. The collected data were used to assess the accuracy of these screening tests in both detecting TB and minimizing false positives.

Unlike previous studies, the researchers found that incorporating some immunological tests for dormant TB infection (TBI tests) improved the screening process. These tests could enhance early diagnosis, particularly for harder-to-detect forms of TB, including extrapulmonary TB (which affects parts of the body outside the lungs) and TB in children. This innovative approach challenges traditional TB testing protocols, which generally reserve TBI tests solely for diagnosing dormant TB. Crucially, combining diagnostic tests for both active and dormant TB allows for the detection of both forms of the disease at the same time. This opportunity for enhanced detection across large populations is particularly valuable to policymakers and public health organizations such as the World Health Organization (WHO) and the European Centre for Disease Prevention and Control.

"Global TB control requires early identification and treatment of TB in risk groups,” said Dr. Dominik Zenner, Clinical Reader in Infectious Disease Epidemiology at Queen Mary who led the research team. “Our novel screening algorithms show that screening for active and dormant TB can be done simultaneously with high accuracy for migrants from countries where TB is common to improve individual and population benefits.”

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.